Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04837209
Title Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital

triple-receptor negative breast cancer


Dostarlimab-gxly + Niraparib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.